DCGI Withdraws Olaparib for Certain Cancer Treatments

India's DCGI orders the withdrawal of Olaparib for specific cancer treatments after reviewing adverse effects and survival data.

Related Keywords

India ,Krishna Kripa ,Astrazeneca ,Astrazeneca Pharma India ,Central Drugs Standard Control Organization ,Some Cancer ,Drug Controller General ,Certain Cancers ,Astrazeneca Pharma India Limited ,Olaparib Tablets ,